By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
Accelerating access to psychedelic based medicines for patients with urgent and unmet needs.
1906 to 2020, from Albert Hofmann's birth to ours >>
Rethinking the clinical trial paradigm.
We’re different. We focus on Real World Data to meet immediate, unmet, clinical needs.
Continued success shows psychedelic medicine is a potential game-changer, but patients could be waiting 5+ years for new treatments to come to market.
Portable, scalable strategy for revenue growth.
Albert Labs is a catalyst leading a collaboration with academic institutions, hospital networks and existing reimbursement mechanisms.
- Leveraging existing clinic & research infrastructure.
- Academic partnerships drive next gen psychedelic R&D.
- Preidenitfied, accessible patient pools.
- Proprietary Real World Data to gain early reimbursement.
- In-house lab results in formulation & delivery IP.
Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.
Let us tell you more.
We will email you to start the conversation.
Meet the experts delivering real world evidence and access to psychedelic medicine to those most in need.
Albert Labs has the people, expertise, and connections to build these unique protocols. Albert's team have delivered successful trials across multiple compounds, conditions and jurisdictions within Europe.
"There is an opportunity here to provide something of real value to patients who are truly suffering."
"The average clinical trial takes 6-12 years and costs over half a billion dollars we can't let patients wait that long."
Previous
Next
UK focus, supplied by Canadian R&D facility.
Application has been made for a dealers license allowing Albert Labs to test, possess, import and export. Proprietary bioreactor cultivation, extraction and formulation protocols using Industry-leading technology.
Faster
Through Real World Evidence we can accelerate innovation and access to patients suffering now and generate revenue along the way.
Focused
Patient focused data and physician usage experience will help unlock reimbursement pathways faster bringing science and continuity to those in need.
Credible
Real World Evidence is quickly becoming the acceptable protocol to assess innovative formulations as effective. Regarded by regulators and policymakers.
Insights
Larger data sets from a breadth of representative patient populations. Real-world insights enable us to develop unique formulations and delivery
<<1906 from Albert Hofmann's birth to ours
Standing on the shoulders of the giants that went before.
We are driven to develop the vision of those that revealed the true power of psychedelics as medicines.
“The outcome of these experiments took place in the framework of systematic pharmaceutical, chemical research.”
- Albert Hofmann, 1938 Novartis Labs (Sandoz) , Basel Switzerland.
Who is Albert?
Albert Hofmann pioneered the discovery and development of psychedelic therapies including LSD & Psilocybin, understanding their therapeutic value first hand.
Let us tell you more.
We will email you to start the conversation.